Industry Developments

BMI View: Leading medical device companies, particularly those based in Europe, will increasingly embrace opportunities in emerging markets. However, they will have to monitor economic... 2011-12-12

BMI View: While Venezuela's increasingly harsh pricing regime looks unlikely to address persistent medicine shortages, President Hugo Chavez's renewed attempts to regulate the country's... 2011-12-07

BMI View: While we are encouraged by a string of recent research and development (R&D) investments in Brazil, it is worth noting the impact of an increasingly government-led healthcare... 2011-12-06

BMI Core View: Drugmakers based in emerging markets will expand their presence in developed countries. Firms in developing countries enjoy low operating costs but have historically... 2011-12-05

BMI View: The same nationalistic sentiments that helped prop up Brazil's domestic pharmaceutical sector have translated into the country's growing clinical trials sector. While more... 2011-12-02

BMI View: Although we view the government's efforts to roll out universal healthcare coverage favourably, Mexico will continue to show signs of being a patchwork healthcare system unless... 2011-12-01

BMI View: Despite having a highly capable domestic research sector and Latin America's first clinical trials registry, Argentina has seen a decline in the number of drugmakers and clinical... 2011-11-30

BMI View: US sales of Lipitor (atorvastatin) will drop by less than expected following patent expiry. This is due to the many franchise preservation strategies employed by Pfizer, namely... 2011-11-30

BMI View: While recent regulatory developments give reason for us maintain our favourable view of Bolivia's drug approvals system and registration process, we believe the country's... 2011-11-29

BMI View: Argentina's government takes healthcare responsibilities seriously but consistently weak regulatory oversight of informal medicine vendors continues to put the public at risk.... 2011-11-28